Emmaus Life Sciences has entered into a licensing agreement with NeoImmuneTech (NIT) that grants NIT exclusive rights to market, sell and distribute Endari and its generic equivalents[7]. Endari is a drug in the form of an oral powder containing L-glutamine that is intended to reduce acute complications of sickle cell anemia in adults and children 5 years of age and older[8]. The drug has been approved by the FDA and is available in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain, and Oman[2][3]. Emmaus Life Sciences is a specialty biopharmaceutical company focused on the treatment of sickle cell anemia[2]. Endari was the first approved drug for the treatment of this disease in nearly 20 years[4]. Emmaus offers financial assistance to patients to help pay the co-pay for the drug and has a support program for qualified patients with no insurance or inadequate insurance[4][5].